Citation analysis for PharmacoEconomics / Springer Healthcare

Citation Profile [Updated: 2022-01-09 21:43:50]

5 Years H

Impact Factor

5 Years IF

Data available in this report

[Raw data] [50 most cited papers] [50 most relevant papers] [cites used to compute IF] [Recent citations ][Frequent citing series ] [more data in EconPapers] [trace new citations] [Missing citations? Add them now] [Incorrect content? Let us know]

Main indicators

Raw Data

	IF	AIF	CIF	IF5	DOC	CDO	CIT	NCI	CCU	D2Y	C2Y	D5Y	C5Y	SC	%SC	CiY	II	AII
1990	0	0.14	0	0	0	0	0		0	0		0			0		0	0.07
1991	0	0.11	0	0	0	0	0		0	0		0			0		0	0.06
1992	0	0.1	0	0	0	0	0		0	0		0			0		0	0.07
1993	0	0.13	0	0	0	0	0		0	0		0			0		0	0.07
1994	0	0.13	0	0	0	0	0		0	0		0			0		0	0.06
1995	0	0.18	0	0	0	0	0		0	0		0			0		0	0.09
1996	0	0.21	0	0	0	0	0		0	0		0			0		0	0.12
1997	0	0.23	0	0	0	0	0		0	0		0			0		0	0.13
1998	0	0.24	0	0	0	0	0		0	0		0			0		0	0.15
1999	0	0.32	0	0	0	0	0		0	0		0			0		0	0.21
2000	0	0.44	0	0	0	0	0		0	0		0			0		0	0.2
2001	0	0.4	0	0	0	0	0		0	0		0			0		0	0.22
2002	0	0.42	0	0	0	0	0		0	0		0			0		0	0.23
2003	0	0.42	0	0	0	0	0		0	0		0			0		0	0.24
2004	0	0.47	0	0	0	0	0		0	0		0			0		0	0.27
2005	0	0.49	0	0	0	0	0		0	0		0			0		0	0.29
2006	0	0.47	0	0	0	0	0		0	0		0			0		0	0.27
2007	0	0.39	0	0	0	0	0		0	0		0			0		0	0.22
2008	0	0.46	0	0	0	0	0		0	0		0			0		0	0.23
2009	0	0.43	0	0	0	0	0		0	0		0			0		0	0.22
2010	0	0.37	0	0	0	0	0		0	0		0			0		0	0.19
2011	0	0.46	0	0	0	0	0		0	0		0			0		0	0.25
2012	0	0.5	0	0	0	0	0		0	0		0			0		0	0.25
2013	0	0.5	0	0	0	0	0		0	0		0			0		0	0.24
2014	0	0.53	0	0	0	0	0		0	0		0			0		0	0.27
2015	0	0.53	0	0	0	0	0		0	0		0			0		0	0.27
2016	0	0.54	0	0	0	0	0		0	0		0			0		0	0.27
2017	0	0.54	0	0	0	0	0		0	0		0			0		0	0.27
2018	0	0.53	0	0	0	0	0		0	0		0			0		0	0.26
2019	0	0.55	0	0	0	0	0		0	0		0			0		0	0.32
2020	0	0.63	0	0	0	0	0		0	0		0			0		0	0.58

IF:	Impact Factor: C2Y / D2Y
AIF:	Average Impact Factor for series in RePEc in year y
CIF:	Cumulative impact factor
IF5:	Impact Factor: C5Y / D5Y
DOC:	Number of documents published in year y
CDO:	Cumulative number of documents published until year y
CIT:	Number of citations to papers published in year y
NCI:	Number of citations in year y
CCU:	Cumulative number of citations to papers published until year y
D2Y:	Number of articles published in y-1 plus y-2
C2Y:	Cites in y to articles published in y-1 plus y-2
D5Y:	Number of articles published in y-1 until y-5
C5Y:	Cites in y to articles published in y-1 until y-5
SC:	selft citations in y to articles published in y-1 plus y-2
%SC:	Percentage of selft citations in y to articles published in y-1 plus y-2
CiY:	Cites in year y to documents published in year y
II:	Immediacy Index: CiY / Documents.
AII:	Average Immediacy Index for series in RePEc in year y

50 most cited documents in this series

#	Title	Cited
1	Integer/Linear Mathematical Programming Models: A Tool for Allocating Healthcare Resources. (2003). Earnshaw, Stephanie R. ; Dennett, Susan L.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:12:p:839-851. Full description at Econpapers \|\| Download paper	19
2	Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies. (2008). Godman, Brian ; Schwabe, Ulrich ; Garattini, Silvio ; Joppi, Roberta . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:2:p:91-98. Full description at Econpapers \|\| Download paper	6
3	Cost of Schizophrenia to UK Society: An Incidence-Based Cost-of-Illness Model for the First 5 Years Following Diagnosis. (1999). Guest, Julian F. ; Cookson, Ron F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:15:y:1999:i:6:p:597-610. Full description at Econpapers \|\| Download paper	3
4	NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective. (2008). Lewis, Gavin ; Earnshaw, Julia . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:9:p:725-727. Full description at Econpapers \|\| Download paper	2
5	Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). (2001). Harris, Anthony ; Mitchell, Andrew ; George, Bethan . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109. Full description at Econpapers \|\| Download paper	2
6	QALYs: Are They Helpful to Decision Makers?. (2006). Caro, Jaime J. ; McGregor, Maurice . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:10:p:947-952. Full description at Econpapers \|\| Download paper	2
7	The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?. (2008). Jommi, Claudio . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:5-15. Full description at Econpapers \|\| Download paper	2
8	Modelling in Health Economic Evaluation: What is its Place? What is its Value?. (2000). Akehurst, Ron . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:5:p:445-459. Full description at Econpapers \|\| Download paper	2
9	European Healthcare Policies for Controlling Drug Expenditure. (2003). Schneeweiss, Sebastian ; Szucs, Thomas D. ; Ess, Silvia M.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:2:p:89-103. Full description at Econpapers \|\| Download paper	2
10	The Economic Impact of Parkinson`s Disease: An Estimation Based on a 3-Month Prospective Analysis. (1998). Rathay, Bernard ; Oertel, Wolfgang H. ; Szucs, Thomas ; Kohne-Volland, Rudolf ; Dodel, Richard C. ; Singer, Marikka ; Scholz, Erich . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:3:p:299-312. Full description at Econpapers \|\| Download paper	1
11	The Cost of Treatment of Alzheimers Disease in The Netherlands: A Regression-Based Simulation Model. (2001). Ruitenberg, Annemieke ; van der Roer, Nicole ; Monique M. B. Breteler, ; Redekop, Ken W. ; McDonnell, Joseph ; Jan J. V. Busschbach, ; Frans F. H. Rutten, ; Goes, Elles . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:4:p:379-390. Full description at Econpapers \|\| Download paper	1
12	Incorporating Carer Effects into Economic Evaluation. (2006). Walker, Mel ; Dixon, Simon ; Salek, Sam . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:1:p:43-53. Full description at Econpapers \|\| Download paper	1
13	Annual Cost of Erectile Dysfunction to UK Society. (1999). Plumb, Jonathan M. ; Guest, Julian F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:16:y:1999:i:6:p:699-709. Full description at Econpapers \|\| Download paper	1
14	The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4. (2008). Mitchell, Andrew ; Scuffham, Paul A. ; Whitty, Jennifer A.. In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:4:p:297-310. Full description at Econpapers \|\| Download paper	1
15	Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers. (2006). Gafni, Amiram ; Birch, Stephen . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:11:p:1121-1131. Full description at Econpapers \|\| Download paper	1
16	Prospective Study Designs in Outcomes Research: The Case of Migraine. (2002). Gomez-Mancilla, Baltazar ; Schonfeld, Warren H. ; Brod, Meryl I. ; Rothermich, Elizabeth A. ; Rowland, Clayton R.. In: PharmacoEconomics. RePEc:wkh:phecon:v:20:y:2002:i:11:p:715-725. Full description at Econpapers \|\| Download paper	1
17	Cost of Illness in Adult Patients with Hypopituitarism. (2000). Bengtsson, Bengt-Ake ; Rosen, Thord ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Ehrnborg, Christer ; Jonsson, Bjorn . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:621-628. Full description at Econpapers \|\| Download paper	1
18	Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review. (2010). Puig-Junoy, Jaume . In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:8:p:649-663. Full description at Econpapers \|\| Download paper	1
19	The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency. (1998). Stevenaert, Achille ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Beckers, Albert . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:395-403. Full description at Econpapers \|\| Download paper	1
20	An Economic Overview of Chronic Obstructive Pulmonary Disease. (2001). Dasbach, Erik J. ; Ruchlin, Hirsch S.. In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:623-642. Full description at Econpapers \|\| Download paper	1
21	Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. (2008). Cruess, Alan F. ; Xu, Xiao ; Knight, Tyler ; Goss, Thomas F. ; Buggage, Ronald ; Mones, Jordi ; Soubrane, Gisele ; Zlateva, Gergana ; Pauleikhoff, Daniel ; Schaefer, Caroline ; Lotery, Andrew . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:57-73. Full description at Econpapers \|\| Download paper	1
22	Expert Judgement in Pharmacoeconomic Studies: Guidance and Future Use. (2000). Crawford, Bruce ; Evans, Christopher . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:545-553. Full description at Econpapers \|\| Download paper	1
23	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. (2003). Nordmann, Alain J. ; Krahn, Murray ; Naglie, Gary ; Detsky, Allan S. ; Logan, Alexander G.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:8:p:573-585. Full description at Econpapers \|\| Download paper	1
24	Cant Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products. (2010). Towse, Adrian ; Garrison, Louis P.. In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:2:p:93-102. Full description at Econpapers \|\| Download paper	1
25	Does Managed Care Fuel Pharmaceutical Industry Growth?. (1998). Deardorff, Frank W. ; Murray, Michael D.. In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:341-348. Full description at Econpapers \|\| Download paper	1
26	Developing Guidance for Budget Impact Analysis. (2001). Hutton, John ; Trueman, Paul ; Drummond, Michael . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:609-621. Full description at Econpapers \|\| Download paper	1

50 most relevant documents in this series (papers most cited in the last two years)

#	Year	Title	Cited

Citing documents used to compute impact factor:

Year	Title

Recent citations

10 most frequent citing series

#		Series	H	Cites

#	Title	Cited
1	Integer/Linear Mathematical Programming Models: A Tool for Allocating Healthcare Resources. (2003). Earnshaw, Stephanie R. ; Dennett, Susan L.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:12:p:839-851. Full description at Econpapers \|\| Download paper	19
2	Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies. (2008). Godman, Brian ; Schwabe, Ulrich ; Garattini, Silvio ; Joppi, Roberta . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:2:p:91-98. Full description at Econpapers \|\| Download paper	6
3	Cost of Schizophrenia to UK Society: An Incidence-Based Cost-of-Illness Model for the First 5 Years Following Diagnosis. (1999). Guest, Julian F. ; Cookson, Ron F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:15:y:1999:i:6:p:597-610. Full description at Econpapers \|\| Download paper	3
4	NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective. (2008). Lewis, Gavin ; Earnshaw, Julia . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:9:p:725-727. Full description at Econpapers \|\| Download paper	2
5	Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). (2001). Harris, Anthony ; Mitchell, Andrew ; George, Bethan . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109. Full description at Econpapers \|\| Download paper	2
6	QALYs: Are They Helpful to Decision Makers?. (2006). Caro, Jaime J. ; McGregor, Maurice . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:10:p:947-952. Full description at Econpapers \|\| Download paper	2
7	The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?. (2008). Jommi, Claudio . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:5-15. Full description at Econpapers \|\| Download paper	2
8	Modelling in Health Economic Evaluation: What is its Place? What is its Value?. (2000). Akehurst, Ron . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:5:p:445-459. Full description at Econpapers \|\| Download paper	2
9	European Healthcare Policies for Controlling Drug Expenditure. (2003). Schneeweiss, Sebastian ; Szucs, Thomas D. ; Ess, Silvia M.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:2:p:89-103. Full description at Econpapers \|\| Download paper	2
10	The Economic Impact of Parkinson`s Disease: An Estimation Based on a 3-Month Prospective Analysis. (1998). Rathay, Bernard ; Oertel, Wolfgang H. ; Szucs, Thomas ; Kohne-Volland, Rudolf ; Dodel, Richard C. ; Singer, Marikka ; Scholz, Erich . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:3:p:299-312. Full description at Econpapers \|\| Download paper	1
11	The Cost of Treatment of Alzheimers Disease in The Netherlands: A Regression-Based Simulation Model. (2001). Ruitenberg, Annemieke ; van der Roer, Nicole ; Monique M. B. Breteler, ; Redekop, Ken W. ; McDonnell, Joseph ; Jan J. V. Busschbach, ; Frans F. H. Rutten, ; Goes, Elles . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:4:p:379-390. Full description at Econpapers \|\| Download paper	1
12	Incorporating Carer Effects into Economic Evaluation. (2006). Walker, Mel ; Dixon, Simon ; Salek, Sam . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:1:p:43-53. Full description at Econpapers \|\| Download paper	1
13	Annual Cost of Erectile Dysfunction to UK Society. (1999). Plumb, Jonathan M. ; Guest, Julian F.. In: PharmacoEconomics. RePEc:wkh:phecon:v:16:y:1999:i:6:p:699-709. Full description at Econpapers \|\| Download paper	1
14	The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4. (2008). Mitchell, Andrew ; Scuffham, Paul A. ; Whitty, Jennifer A.. In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:4:p:297-310. Full description at Econpapers \|\| Download paper	1
15	Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers. (2006). Gafni, Amiram ; Birch, Stephen . In: PharmacoEconomics. RePEc:wkh:phecon:v:24:y:2006:i:11:p:1121-1131. Full description at Econpapers \|\| Download paper	1
16	Prospective Study Designs in Outcomes Research: The Case of Migraine. (2002). Gomez-Mancilla, Baltazar ; Schonfeld, Warren H. ; Brod, Meryl I. ; Rothermich, Elizabeth A. ; Rowland, Clayton R.. In: PharmacoEconomics. RePEc:wkh:phecon:v:20:y:2002:i:11:p:715-725. Full description at Econpapers \|\| Download paper	1
17	Cost of Illness in Adult Patients with Hypopituitarism. (2000). Bengtsson, Bengt-Ake ; Rosen, Thord ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Ehrnborg, Christer ; Jonsson, Bjorn . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:621-628. Full description at Econpapers \|\| Download paper	1
18	Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review. (2010). Puig-Junoy, Jaume . In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:8:p:649-663. Full description at Econpapers \|\| Download paper	1
19	The Burden of Illness of Hypopituitary Adults with Growth Hormone Deficiency. (1998). Stevenaert, Achille ; Roijen, Leona Hakkaart-van ; Frans F. H. Rutten, ; Beckers, Albert . In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:395-403. Full description at Econpapers \|\| Download paper	1
20	An Economic Overview of Chronic Obstructive Pulmonary Disease. (2001). Dasbach, Erik J. ; Ruchlin, Hirsch S.. In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:623-642. Full description at Econpapers \|\| Download paper	1
21	Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study. (2008). Cruess, Alan F. ; Xu, Xiao ; Knight, Tyler ; Goss, Thomas F. ; Buggage, Ronald ; Mones, Jordi ; Soubrane, Gisele ; Zlateva, Gergana ; Pauleikhoff, Daniel ; Schaefer, Caroline ; Lotery, Andrew . In: PharmacoEconomics. RePEc:wkh:phecon:v:26:y:2008:i:1:p:57-73. Full description at Econpapers \|\| Download paper	1
22	Expert Judgement in Pharmacoeconomic Studies: Guidance and Future Use. (2000). Crawford, Bruce ; Evans, Christopher . In: PharmacoEconomics. RePEc:wkh:phecon:v:17:y:2000:i:6:p:545-553. Full description at Econpapers \|\| Download paper	1
23	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. (2003). Nordmann, Alain J. ; Krahn, Murray ; Naglie, Gary ; Detsky, Allan S. ; Logan, Alexander G.. In: PharmacoEconomics. RePEc:wkh:phecon:v:21:y:2003:i:8:p:573-585. Full description at Econpapers \|\| Download paper	1
24	Cant Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products. (2010). Towse, Adrian ; Garrison, Louis P.. In: PharmacoEconomics. RePEc:wkh:phecon:v:28:y:2010:i:2:p:93-102. Full description at Econpapers \|\| Download paper	1
25	Does Managed Care Fuel Pharmaceutical Industry Growth?. (1998). Deardorff, Frank W. ; Murray, Michael D.. In: PharmacoEconomics. RePEc:wkh:phecon:v:14:y:1998:i:4:p:341-348. Full description at Econpapers \|\| Download paper	1
26	Developing Guidance for Budget Impact Analysis. (2001). Hutton, John ; Trueman, Paul ; Drummond, Michael . In: PharmacoEconomics. RePEc:wkh:phecon:v:19:y:2001:i:6:p:609-621. Full description at Econpapers \|\| Download paper	1

PharmacoEconomics / Springer Healthcare | Adis